Drug intelligence / Profile preview

8β-VE2

Development stage
Preclinical
Lead developer
Bayer
Modality
Small Molecules
Administration
Used In Research Applications; Primarily Administered In Vitro Or By Injection In Animal Studies
01

Overview

8β-VE2 is a **synthetic estrogen** and a highly potent and selective **agonist of estrogen receptor beta (ERβ)**, used primarily as a research tool. It exhibits around 190-fold higher potency for ERβ over ERα in transactivation assays and a marked selectivity: 93-fold in rat and 180-fold in human for ERβ relative to ERα[1][6][9]. In animal studies, 8β-VE2 selectively stimulates ERβ-mediated biological effects (e.g., skeletal muscle growth, follicular development) and lacks typical ERα-mediated uterotrophic activity[1]. It is also used in research involving prostate cancer and muscle regeneration due to its selective anabolic and pro-apoptotic effects in certain tissues[5][4][1].

Other names
8β-ve28β-vinylestradiol8β-vinylestra-1,3,5(10)-triene-3β,17β-diol8-Ethenylestra-1,3,5(10)-triene-3,17-diol(17β)-8-ethenylestra-1,3,5(10)-triene-3,17-diol8β-Vinylestra-1,3,5(10)-triene-3,17β-ol
02

Targets

ESR2 (ERβ)

Beyond the preview

Go deeper on 8β-VE2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 8β-VE2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call